CARdiAc Mri and BiOLogical samplEs at the Acute Phase of a Myocardial Infarction (CARAMBOLE)

Myocardial Infarction Clinical Trial

— CARAMBOLE  

Official title:

Cardiac MRI and Biological Samples at the Acute Phase of a Myocardial Infarction

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06278519
• Other study ID #: CARAMBOLE
• Status: Recruiting
• Phase: N/A
• Start date: March 1, 2024
• Est. completion date: September 1, 2026

Study information

• Verified date: March 2024
• Source: Poitiers University Hospital
• Contact: Claire Bouleti, MD
• Phone: +33 5 49 44 43 25
• Email: claire.bouleti[@]chu-poitiers.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

ST-Segment Elevation Myocardial infarction (STEMI) corresponding to acute occlusion of cornary artery is the most severe ischemic myocardial disease and a leading cause of mortality of heart failure worldwide. Although acute mortality from STEMI has decreased over the last decades, the prognosis remains pejorative and difficult to anticipate. The best management of STEMI patients depends of predictive factors of clinical prognosis and justifies an active research of these factors, in particular the mechanisms leading to deleterious left ventricular remodeling, myocardial inflammation, reperfusion injury including the no-reflow phenomenon which is a major determinant of heart failure. Cohorts of consecutive STEMI patients, with a comprehensive assessment of clinical, biological and imaging parameters are needed to offer the basis for new hypothese for research or interventions and to precisely evaluate the quality of care provided. The main objective of this study is to identify new markers: clinical, biological and imaging, treatment response and prognosis after STEMI. Secondary objectives of the CARAMBOLE cohort are to establish a comprehensive clinical databse, completed with biological samples and imaging data, that can be used in the following areas: - Descriptive epidemiology of STEMI and myocardial reperfusion - Evaluation of the clinical implications of the realization of a cardiac MRI at the acute phase of STEMI (regarding no-reflow, LVEF, intra cardiac thrombi) - Treatments observatory: safety, efficacy, indication of treatments provided in real life compared to the treatments recommended, adherence to treatments, costs - Quality of life, personal, familial, social and professional consequences of myocardial infarction - Research of new diagnostic and prognosis biomarkers - Research projects (e.g risk of developping cgnitive disorders in patients with STEMI as compared to the general population) Participants will undergo: - a cardiac MRI at the acute phase of their STEMI (5 +/- 3 days) then at 1 year follow-up - biological samples including blood, urinary and feces samples, at the acute phase of their STEMI (from admission and up to 8 days) then at 1 year follow-up - questionnaire assessment regarding their quality of life, cognitive status,and socio-economic conditions at the acute phase and 1 year follow-up of their STEMI.

Description:

Myocardial infarction is one of the leading causes of morbi-mortality, causing 75% of cases of sudden death in adults over 35 years of age and more than half of chronic heart failure. Despite the progress made, based on French data from the CIRCUS study and the FAST-MI registry, all-cause mortality at 1 year remained high at around 8% and the rate of occurrence of composite events (death, heart failure, myocardial infarction, revascularization, stroke) estimated around 25%. ST-segment elevation myocardial infarction (STEMI) is the most severe form of ischemic myocardial disease. The recommended treatment is the quickest possible unblocking of the coronary artery responsible for STEMI, by coronary angioplasty (treatment of choice if time limits are compatible) or, more rarely, thrombolysis. However, this revascularization causes undesirable collateral effects with tissue edema, intra-myocardial hemorrhages, microvascular obstruction and local inflammation which contribute to significantly aggravate myocardial damage. These "reperfusion injuries" increase the risk of Left Ventricular (LV) dysfunction. Thus, immediate mortality decreases but the incidence of heart failure following STEMI increases. Several other parameters associated with a poor prognosis remain to this day incompletely understood and treated: deleterious left ventricular remodeling (LVR), post-infarction inflammation, no-reflow. Furthermore, performing a systematic MRI at the acute phase of STEMI will allow to assess the real prevalence of intra LV thrombi and to treat them before hospital discharge. Indeed, the prevalence of intraLV thrombi is estimated around 20% but only 16% are diagnosed during the stay in the Cardiology Intensive Care Unit (CICU) (low sensitivity of echocardiography, lack of availability of cardiac MRI) . These patients must be treated with anticoagulants to limit the embolic phenomena of intra LV thrombi, in particular strokes, but most patients therefore do not benefit from this treatment when leaving the hospital since MRI is not performed in the acute phase in most centers due to lack of availability. The organization of prospective cohorts with well-documented biological and imaging collections, in particular the systematic use of myocardial MRI, and monitoring of events at 1 year, will thus make it possible to better understand the complex pathophysiology of these deleterious phenomena, their clinical consequences, to propose research hypotheses and ultimately, to developp innovative and personalized treatments.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: September 1, 2026
• Est. primary completion date: September 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient =18 years old, hospitalised in cardiology departments at the C.H.U. of Poitiers
• Myocardial infarction type 1, 2 or 3 according to the 4th universal definition, with elevation of ST segment =0.2 milliVolt in two contiguous derivations of the ECG.
• Patient able to comply with study procedures
• Patient legally free and not subject to any custody, guardianship, tutelage or subordination measures
• Informed consent signed by the patient/relative or trusted person after clear and complete information about the clinical investigation.

Exclusion Criteria:

• Subject with contraindication to MRI : pregnancy, ocular metallic foreign body (accidental or other chips), pace-maker incompatible with MRI, foreign ferromagnetic ocular or cerebral bodies, cochlear implants and in general all electronic medical material immovably implanted and incompatible with MRI; metallic heart valve of 1st generation, vascular clips formerly implanted on cranial aneurysm, severe renal insufficiency
• Patient suffering from claustrophobia
• Hypersensitivity to gadoteric acid, to meglumine or to a drug containing gadolinium
• patients with insufficient venous access for contrast medium injection.
• Participation in another interventional study with an investigational drug or device, which, in the judgment of the investigator, could interfere with the present study
• Patients not benefiting from a Social Security scheme or not benefiting from it through a third party
• Persons benefitting from enhanced protection, namely minors, pregnant women, persons deprived of their liberty by a judicial or administrative decision, patients staying in a health or social establishment, adults under legal protection

Related Conditions & MeSH terms

• Infarction
• Myocardial Infarction

Intervention

Biological:
• Blood, urinary and feces collection
Blood, urinary and feces collection, at inclusion during acute phase of STEMI, and one year after inclusion visit.

Device:
• Cardiac MRI
Cardiac MRI at the acute phase of STEMI (Day 5 +/- 3) and at 1-year follow-up

Other:
• Quality of life and cognitive status questionnaire
Quality of life and cognitive status questionnaire at the acute phase of STEMI and at 1-year follow-up

Locations

Country	Name	City	State
France	C.H.U. of Poitiers	Poitiers

Sponsors (2)

Lead Sponsor	Collaborator
Poitiers University Hospital	Fédération Française de Cardiologie

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Major Adverse cardiac Events (MACE)	MACE (death, recurrence of myocardial infarction, ischemic stroke, hospitalization for heart failure, unplanned coronary revascularization) will be assessed through medical records and clinical follow-up	Up to 1 year after STEMI
Secondary	Infarct size	Infarct size will be measured on Cardiac MRI	Up to 8 days after STEMI
Secondary	Infarct size	Infarct size will be measured on Cardiac MRI	1 year follow-up after STEMI
Secondary	No-reflow size	No-reflow size will be measured on Cardiac MRI	Up to 8 days after STEMI
Secondary	No-reflow size	No-reflow size will be measured on Cardiac MRI	1 year follow-up after STEMI
Secondary	Cardiac enzymes rate	Cardiac enzymes rate will be analyzed on blood samples	H0 (admission in Intensive Cardiac Care Unit)
Secondary	Cardiac enzymes rate	Cardiac enzymes rate will be analyzed on blood samples	H24 (24 hours after reperfusion)
Secondary	Cardiac enzymes rate	Cardiac enzymes rate will be analyzed on blood samples	H48 (48 hours after reperfusion)
Secondary	Cardiac enzymes rate	Cardiac enzymes rate will be analyzed on blood samples	1 year follow-up after STEMI
Secondary	Inflammatory markers rate	Inflammatory markers rate will be analyzed on blood samples	H0 (admission in Intensive Cardiac Care Unit)
Secondary	Inflammatory markers rate	Inflammatory markers rate will be analyzed on blood samples	H24 (24 hours after reperfusion)
Secondary	Inflammatory markers rate	Inflammatory markers rate will be analyzed on blood samples	H48 (48 hours after reperfusion)
Secondary	Inflammatory markers rate	Inflammatory markers rate will be analyzed on blood samples	1 year follow-up after STEMI
Secondary	Gut microbiota profiling	Gut microbiota will be assessed on feces samples. Metagenomic sequencing and 16S ribosomal ribonuleic acid (RNA) gene sequencing will be applied to investigate gut microbiota richness, diversity and composition.	Up to 8 days after STEMI
Secondary	Gut microbiota profiling	Gut microbiota will be assessed on feces samples. Metagenomic sequencing and 16S ribosomal ribonuleic acid (RNA) gene sequencing will be applied to investigate gut microbiota richness, diversity and composition.	1 year follow-up after STEMI
Secondary	Genitourinary microbiota profiling	Genitourinary microbiota will be assessed on urine samples. Metagenomic sequencing and 16S ribosomal ribonuleic acid (RNA) gene sequencing will be applied to investigate genitourinary microbiota richness, diversity and composition.	Up to 8 days after STEMI
Secondary	Genitourinary microbiota profiling	Genitourinary microbiota will be assessed on feces samples. Metagenomic sequencing and 16S ribosomal ribonuleic acid (RNA) gene sequencing will be applied to investigate genitourinary microbiota richness, diversity and composition.	1 year follow-up after STEMI
Secondary	EQ-5D-3L score (European Quality of Life 5 Dimensions 3 Level version)	Patients' quality of life will be evaluated by the EQ-5D-3L questionnaire, which ranges from 5 to 15, with a highest score meaning a worse outcome	Up to 8 days after STEMI
Secondary	EQ-5D-3L score (European Quality of Life 5 Dimensions 3 Level version)	Patients' quality of life will be evaluated by the EQ-5D-3L questionnaire, which ranges from 5 to 15, with a highest score meaning a worse outcome	1 year follow-up after STEMI
Secondary	Codex test	Patients' cognitive status will be evaluated by the Codex test	Up to 8 days after STEMI
Secondary	Codex test	Patients' cognitive status will be evaluated by the Codex test	1 year follow-up after STEMI